Walgreens Boots Alliance ... (WBA)
11.01
-0.02 (-0.18%)
At close: Apr 25, 2025, 3:59 PM
11.01
0.00%
After-hours: Apr 25, 2025, 05:54 PM EDT
Walgreens Boots Alliance Revenue Breakdown
| Period Ending | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 | May 31, 2022 | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 | Nov 30, 2020 | Aug 31, 2020 | May 31, 2020 | Feb 29, 2020 | Nov 30, 2019 | Aug 31, 2019 | May 31, 2019 | Feb 28, 2019 | Nov 30, 2018 | May 31, 2018 | Feb 28, 2018 | Nov 30, 2017 | Aug 31, 2017 | May 31, 2017 | Feb 28, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International Reportable Segment Revenue | 6.42B | 5.97B | 5.73B | 6.02B | 5.83B | 212M | 11.15B | 5.65B | 5.19B | 5.14B | 5.3B | 5.56B | 5.82B | 5.51B | 5.29B | 5.42B | 27.16B | 26.97B | 27.36B | 27.25B | 26.13B | 26.04B | 26.51B | 26.26B | 25.72B | 25.92B | 24.48B | 22.49B | 22.3B | 22.53B | 21.81B |
| International Reportable Segment Revenue Growth | +7.60% | +4.26% | -4.90% | +3.26% | +2650.94% | -98.10% | +97.24% | +8.90% | +0.87% | -3.03% | -4.64% | -4.38% | +5.65% | +4.14% | -2.53% | -80.03% | +0.73% | -1.43% | +0.41% | +4.26% | +0.35% | -1.78% | +0.97% | +2.08% | -0.76% | +5.88% | +8.84% | +0.84% | -1.01% | +3.27% | n/a |
| Retail Pharmacy USA Revenue | 30.87B | 87.28B | 28.5B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Retail Pharmacy USA Revenue Growth | -64.63% | +206.20% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Aug 31, 2024 | Aug 31, 2023 | Aug 31, 2022 | Aug 31, 2021 | Aug 31, 2020 | Aug 31, 2019 | Aug 31, 2018 | Aug 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| United Kingdom Revenue | 9.55B | 8.98B | 8.89B | 112B | 107.7B | 104.53B | 98.39B | 87.3B |
| United Kingdom Revenue Growth | +6.30% | +1.01% | -92.06% | +4.00% | +3.03% | +6.24% | +12.70% | n/a |
| United States Revenue | 124.18B | 116.88B | 110.87B | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +6.24% | +5.42% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Nov 30, 2024 | Aug 31, 2024 | May 31, 2024 | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 | May 31, 2022 | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 | Nov 30, 2020 | Aug 31, 2020 | May 31, 2020 | Feb 29, 2020 | Nov 30, 2019 | Aug 31, 2019 | May 31, 2019 | Feb 28, 2019 | Nov 30, 2018 | Aug 31, 2018 | May 31, 2018 | Feb 28, 2018 | Nov 30, 2017 | Aug 31, 2017 | May 31, 2017 | Feb 28, 2017 | Nov 30, 2016 | Aug 31, 2016 | May 31, 2016 | Feb 29, 2016 | Nov 30, 2015 | Aug 31, 2015 | May 31, 2015 | Feb 28, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 7.01B | 6.95B | 6.39B | 7.92B | 6.85B | 6.99B | 7.12B | 6.93B | 13.16B | 7.32B | 7.02B | 6.57B | 6.39B | 6.65B | 6.12B | 6.03B | 5.79B | 6.21B | 7.88B | 5.91B | 6.26B | 6.41B | 6.24B | 6.32B | 6.28B | 6.11B | 6.24B | 6.32B | 5.91B | 6.22B | 5.71B | 6.12B | 5.69B | 5.83B | 5.9B | 6.01B | 5.95B | 6.43B | 6.08B | 5.61B |
| Selling, General, and Administrative Revenue Growth | +0.96% | +8.68% | -19.29% | +15.62% | -1.99% | -1.87% | +2.73% | -47.30% | +79.75% | +4.29% | +6.92% | +2.72% | -3.89% | +8.73% | +1.44% | +4.09% | -6.73% | -21.23% | +33.42% | -5.64% | -2.28% | +2.77% | -1.34% | +0.64% | +2.73% | -1.96% | -1.36% | +6.95% | -4.95% | +8.86% | -6.73% | +7.70% | -2.39% | -1.32% | -1.73% | +0.94% | -7.44% | +5.74% | +8.46% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |